These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 39098760)

  • 1. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance.
    Chen Y; Lu A; Hu Z; Li J; Lu J
    Cancer Lett; 2024 Sep; 599():217146. PubMed ID: 39098760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of erbB3 receptor to overcome resistance in cancer treatment.
    Ma J; Lyu H; Huang J; Liu B
    Mol Cancer; 2014 May; 13():105. PubMed ID: 24886126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.
    Kiavue N; Cabel L; Melaabi S; Bataillon G; Callens C; Lerebours F; Pierga JY; Bidard FC
    Oncogene; 2020 Jan; 39(3):487-502. PubMed ID: 31519989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of erbB3 receptors in cancer therapeutic resistance.
    Lee Y; Ma J; Lyu H; Huang J; Kim A; Liu B
    Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):190-8. PubMed ID: 24449784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo.
    Foreman PK; Gore M; Kobel PA; Xu L; Yee H; Hannum C; Ho H; Wang SM; Tran HV; Horowitz M; Horowitz L; Bhatt RR
    Mol Cancer Ther; 2012 Jul; 11(7):1411-20. PubMed ID: 22553357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
    Verlingue L; Hollebecque A; Lacroix L; Postel-Vinay S; Varga A; El Dakdouki Y; Baldini C; Balheda R; Gazzah A; Michot JM; Marabelle A; Mir O; Arnedos M; Rouleau E; Solary E; De Baere T; Angevin E; Armand JP; Michiels S; André F; Deutsch E; Scoazec JY; Soria JC; Massard C
    Eur J Cancer; 2018 Mar; 92():1-10. PubMed ID: 29413684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
    Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
    Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
    Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.
    Stern DF
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):215-23. PubMed ID: 18454306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.
    Aurisicchio L; Marra E; Luberto L; Carlomosti F; De Vitis C; Noto A; Gunes Z; Roscilli G; Mesiti G; Mancini R; Alimandi M; Ciliberto G
    J Cell Physiol; 2012 Oct; 227(10):3381-8. PubMed ID: 22213458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into ErbB3 function and therapeutic targeting in cancer.
    Hafeez U; Parslow AC; Gan HK; Scott AM
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1057-1074. PubMed ID: 32981377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
    Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
    Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
    Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
    Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK
    Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.